APPI Health Group

appihealthgroup.com

The APPI has enjoyed immense success with training Physiotherapists and equivalent degree therapists in the APPI Pilates method. Our success relies on our research based approach to Pilates training. As physiotherapists, we recognise the demand for more specific Pilates training which targets the higher theoretical and practical experience of higher degree therapists. The APPI method presents the most current research relevant to Pilates and teaches a realistic framework of exercises to apply in the clinical setting.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

LANTERN PHARMA’S PROPRIETARY A.I. PLATFORM SURPASSES 450 MILLION DATA POINTS ACCELERATING ONCOLOGY DRUG DEVELOPMENT AND DRUG RESPONSE PREDICTION

Lantern Pharma | June 30, 2020

news image

Lantern Pharma, a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and...

Read More

BUSINESS INSIGHTS

TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT AND PIPE OFFERING PRICED AT-THE-MARKET

Titan Pharmaceuticals, Inc. | February 03, 2022

news image

Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...

Read More

NEW AMR ACTION FUND STEPS IN TO SAVE COLLAPSING ANTIBIOTIC PIPELINE WITH PHARMACEUTICAL INDUSTRY INVESTMENT OF US$1 BILLION

AMR Action Fund | July 09, 2020

news image

Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resi...

Read More

BUSINESS INSIGHTS

CATO SMS ACQUIRES NUVENTRA IN ORDER TO EXPAND ITS DRUG DEVELOPMENT OFFERING INTO CLINICAL PHARMACOLOGY

Nuventra, CATO SMS | May 27, 2021

news image

CATO SMS, a global provider of regulatory and clinical research services, announced today the acquisition of Nuventra, Inc., to expand its offering into the critical area of clinical pharmacology. Nuventra, headquartered in Durham, North Carolina, is a leading company in clinical pharmacology science and services. The acquisition expands CATO SMS's portfolio of specialized solutions that help biopharmaceutical companies with drug development by providing a key set of skills targeted at signi...

Read More
news image

LANTERN PHARMA’S PROPRIETARY A.I. PLATFORM SURPASSES 450 MILLION DATA POINTS ACCELERATING ONCOLOGY DRUG DEVELOPMENT AND DRUG RESPONSE PREDICTION

Lantern Pharma | June 30, 2020

Lantern Pharma, a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and...

Read More
news image

BUSINESS INSIGHTS

TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT AND PIPE OFFERING PRICED AT-THE-MARKET

Titan Pharmaceuticals, Inc. | February 03, 2022

Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...

Read More
news image

NEW AMR ACTION FUND STEPS IN TO SAVE COLLAPSING ANTIBIOTIC PIPELINE WITH PHARMACEUTICAL INDUSTRY INVESTMENT OF US$1 BILLION

AMR Action Fund | July 09, 2020

Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resi...

Read More
news image

BUSINESS INSIGHTS

CATO SMS ACQUIRES NUVENTRA IN ORDER TO EXPAND ITS DRUG DEVELOPMENT OFFERING INTO CLINICAL PHARMACOLOGY

Nuventra, CATO SMS | May 27, 2021

CATO SMS, a global provider of regulatory and clinical research services, announced today the acquisition of Nuventra, Inc., to expand its offering into the critical area of clinical pharmacology. Nuventra, headquartered in Durham, North Carolina, is a leading company in clinical pharmacology science and services. The acquisition expands CATO SMS's portfolio of specialized solutions that help biopharmaceutical companies with drug development by providing a key set of skills targeted at signi...

Read More